background
hydroxychloroquin
chloroquin
use
extens
malaria
rheumatolog
condit
although
gener
safe
well
toler
potenti
lethal
overdos
two
drug
candid
prevent
treatment
vitro
data
suggest
high
concentr
thu
high
dose
need
benefit
yet
convinc
evid
clinic
effect
nevertheless
alreadi
use
wide
fatal
accident
overdos
report
method
individu
data
prospect
studi
french
patient
taken
intent
chloroquin
overdos
manag
nation
toxicolog
intens
care
unit
pari
pool
bayesian
logist
regress
use
estim
concentrationfat
curv
probabl
fatal
iatrogen
toxic
chloroquin
regimen
current
triall
treatment
estim
combin
pharmacokineticpharmacodynam
model
find
total
patient
studi
die
steep
sigmoid
relationship
admiss
whole
blood
chloroquin
concentr
death
concentr
credibl
interv
ci
associ
greater
mortal
base
peak
concentr
absolut
fatal
ratio
high
dose
arm
chloroquin
base
equival
adult
dose
given
twice
daili
ten
day
recent
termin
trial
estim
adult
ci
adult
ci
regimen
result
peak
concentr
adult
weigh
high
dose
regimen
triall
current
result
peak
concentr
adult
weight
interpret
highdos
chloroquin
treatment
regimen
result
whole
blood
chloroquin
concentr
major
patient
result
lifethreaten
cardiovascular
toxic
search
pubm
use
term
chloroquin
hydroxychloroquin
suicid
intox
poison
concentr
mice
return
result
exclud
review
case
report
concentr
measur
post
mortem
healthi
volunt
studi
anim
studi
laboratori
studi
public
retain
case
report
hospit
cohort
case
report
exhibit
signific
bia
toward
individu
high
concentr
surviv
hospit
cohort
extract
data
manual
one
obtain
origin
data
two
ad
valu
studi
provid
object
methodolog
evalu
risk
overdos
chloroquin
treatment
prevent
regimen
current
triall
use
assess
formal
riskbenefit
tradeoff
administ
larg
dose
treatment
implic
avail
evid
studi
chloroquin
hydroxychloroquin
treatment
must
balanc
signific
toxic
high
dose
treatment
regimen
expect
therapeut
benefit
major
treatment
regimen
prevent
regimen
investig
satisfactori
safeti
margin
chloroquin
hydroxychloroquin
close
relat
drug
use
treatment
malaria
amoebiasi
rheumatolog
condit
late
chloroquin
drug
choic
treatment
malaria
hundr
tonn
consum
annual
sinc
use
declin
widespread
resist
plasmodium
falciparum
today
greater
use
hydroxychloroquin
rheumatoid
arthriti
discoid
system
lupu
erythematosu
sle
chloroquin
hydroxychloroquin
weak
antivir
broad
rang
activ
includ
flavivirus
retrovirus
coronavirus
randomis
clinic
trial
evalu
drug
prevent
treatment
way
rel
weak
antivir
activ
vero
cell
cultur
motiv
triall
higher
load
mainten
dose
usual
given
malaria
hepat
amoebiasi
caus
concern
potenti
cardiovascular
toxic
nevertheless
despit
lack
convinc
evid
clinic
benefit
drug
use
extens
prevent
treatment
across
world
patient
need
treatment
malaria
rheumatolog
condit
difficulti
obtain
borba
et
al
report
preliminari
result
randomis
trial
brazil
two
dose
regimen
chloroquin
treatment
studi
clinicaltrialsgov
trial
stop
earli
recruit
patient
cardiac
toxic
greater
mortal
higher
dose
group
two
patient
given
higher
dose
regimen
develop
ventricular
tachycardia
death
patient
group
develop
electrocardiograph
qtcf
interv
compar
lower
dose
group
high
dose
regimen
compris
base
chloroquin
administ
twice
daili
ten
day
substanti
higher
recommend
malaria
rheumatolog
condit
repres
standard
malaria
load
dose
repeat
time
hour
interv
chloroquin
danger
overdos
use
extens
suicid
high
concentr
chloroquin
caus
hypotens
arrhythmia
coma
ard
fatal
cardiac
arrest
zimbabw
mortal
chloroquin
overdos
approxim
six
time
higher
drug
franc
earli
suicid
epidem
follow
public
book
entitl
suicid
mode
demploi
suicid
howto
guid
unfortun
experi
allow
characteris
factor
associ
death
chloroquin
overdos
outcom
chloroquin
selfpoison
depend
dose
ingest
delay
reach
hospit
qualiti
intens
care
support
use
blood
concentr
measur
taken
selfpoison
patient
manag
experienc
intensivist
french
nation
referr
centr
allow
develop
pharmacokineticpharmacodynam
model
estim
relationship
chloroquin
dose
fatal
outcom
model
appli
treatment
regimen
current
clinic
trial
standard
malaria
treatment
regimen
comparison
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
largest
prospect
studi
cohort
selfpoison
chloroquin
assembl
nation
clinic
toxicolog
unit
pari
franc
et
toxicologiqu
clinic
laboratori
detail
cohort
publish
detail
previous
extens
experi
gather
clinic
toxicolog
unit
establish
standard
care
includ
mechan
ventil
appropri
sedat
optimum
use
inotrop
vasopressor
prehospit
care
provid
emerg
physician
mobil
intens
care
unit
unit
could
perform
electrocardiogram
well
advanc
life
support
whole
blood
chloroquin
concentr
measur
admiss
spectrophotometri
distinguish
parent
compound
biologiclli
activ
desethyl
metabolit
vari
time
subsequ
origin
data
avail
patient
studi
patient
includ
prospect
studi
histori
attempt
suicid
chloroquin
present
initi
sampl
whole
blood
patient
studi
multipl
whole
blood
chloroquin
measur
taken
first
hour
hospit
stay
number
time
sampl
vari
case
origin
data
avail
concentr
outcom
extract
graph
public
figur
whole
blood
chloroquin
concentr
outcom
could
determin
approxim
patient
data
extract
use
web
version
webplotdigit
http
automerisio
webplotdigit
also
conduct
literatur
review
publish
case
report
hospit
cohort
chloroquin
poison
extract
data
case
report
patient
whole
blood
plasma
chloroquin
concentr
report
analys
case
report
blood
plasma
concentr
obtain
antemortem
post
mortem
redistribut
chloroquin
tissu
blood
unknown
howev
data
case
report
exhibit
signific
bia
toward
patient
high
concentr
surviv
ie
unusu
case
exclud
final
model
whole
blood
chloroquin
concentr
follow
selfpoison
determin
use
ultraviolet
spectrophotometri
wavelength
method
differenti
chloroquin
biolog
activ
desethyl
metabolit
pharmacokinet
model
data
healthi
subject
patient
malaria
use
predict
like
exposur
thu
toxic
risk
regimen
evalu
current
chloroquin
complex
pharmacokinet
properti
characteris
enorm
volum
distribut
termin
elimin
halflif
month
whole
blood
current
prefer
matrix
concentr
significantli
higher
plasma
concentr
bind
red
blood
cell
leukocyt
platelet
two
model
fit
nonmem
icon
develop
solut
ellicott
citi
md
nonmem
simul
code
avail
onlin
see
github
repositori
link
first
twocompart
disposit
model
use
whole
blood
measur
vivax
malaria
patient
treat
standard
basekg
regimen
three
day
n
concentr
measur
allometr
scale
bodi
weight
expon
fix
clearanc
paramet
volum
paramet
ad
model
predict
concentr
differ
bodi
weight
second
model
threecompart
model
fit
plasma
chloroquin
concentr
healthi
volunt
took
singl
base
equival
dose
chloroquin
without
primaquin
n
individu
took
singl
dose
two
separ
occas
similar
allometr
scale
appli
publish
estim
plasma
blood
ratio
vari
consider
review
select
scale
ratio
predict
median
concentr
model
match
median
concentr
whole
blood
three
publish
studi
long
durat
followup
provid
plasma
whole
blood
concentr
ratio
five
potenti
chloroquin
adult
treatment
regimen
one
malaria
treatment
regimen
simul
base
twice
daili
day
triall
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
base
load
dose
hour
follow
base
twice
daili
start
hour
nine
day
except
load
dose
ident
regimen
recommend
health
commiss
guangdong
provinc
base
load
dose
day
hour
follow
base
twice
daili
start
hour
six
day
weightbas
dose
regimen
target
load
dose
hour
basekg
follow
mainten
dose
day
approxim
use
base
whole
tablet
weightbas
dose
regimen
target
load
dose
hour
basekg
follow
mainten
dose
day
approxim
use
base
whole
tablet
flat
malaria
dose
regimen
base
day
follow
base
day
rang
weight
regimen
flat
dose
regimen
ie
weightbas
regimen
simul
weight
rang
kg
compar
relationship
admiss
whole
blood
chloroquin
desethyl
metabolit
concentr
death
use
logist
regress
maximum
likelihood
fit
data
gather
retrospect
n
data
collect
prospect
n
retrospect
data
gave
substanti
differ
result
much
higher
probabl
death
approxim
versu
see
figur
therefor
exclud
retrospect
studi
patient
report
retain
prospect
studi
patient
gave
total
uniqu
observ
model
probabl
death
function
log
whole
blood
peak
chloroquin
concentr
use
bayesian
logist
regress
peak
concentr
consid
latent
variabl
unobserv
patient
reach
peak
hospit
admiss
patient
admiss
blood
concentr
measur
n
peak
concentr
consid
observ
patient
multipl
concentr
measur
whose
peak
concentr
reach
hospit
admiss
n
model
attempt
estim
individu
peak
concentr
patient
peak
observ
rather
averag
differ
log
scale
peak
admiss
concentr
consid
bia
correct
term
assum
probabl
death
condit
peak
concentr
whose
blood
concentr
peak
peak
hospit
admiss
realiti
assumpt
like
incorrect
patient
whose
level
peak
hospit
admiss
receiv
support
hospit
care
rapidli
rel
time
peak
concentr
peak
hospit
admiss
howev
extent
bia
introduc
assumpt
unmeasur
model
relationship
whole
blood
chloroquin
concentr
fatal
outcom
use
correct
factor
account
desethyl
metabolit
includ
assay
measur
hour
post
ingest
desethyl
metabolit
account
approxim
total
concentr
measur
note
valu
directli
identifi
data
good
priori
estim
use
data
individu
peak
hospit
admiss
construct
inform
prior
distribut
bayesian
posterior
distribut
model
paramet
use
inform
prior
distribut
four
paramet
intercept
term
normal
distribut
mean
eg
chanc
die
whole
blood
concentr
standard
deviat
coeffici
log
concentr
normal
distribut
mean
standard
deviat
bia
term
given
exponenti
prior
rate
estim
individu
peak
hospit
admiss
metabolit
correct
factor
given
normal
prior
mean
standard
deviat
standard
deviat
estim
chloroquin
metabolit
measur
malaria
patient
uncertainti
around
fit
report
centr
credibl
interv
model
fit
use
stan
implement
r
posterior
sampl
drawn
independ
chain
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
first
half
discard
burnin
second
half
thin
everi
sampl
result
posterior
sampl
use
characteris
posterior
concentrationrespons
curv
mix
assess
agreement
chain
traceplot
comparison
prior
posterior
distribut
given
supplementari
figur
code
data
openli
avail
github
http
githubcomjwatowatsonchloroquineconcentrationfat
simul
pharmacokinet
profil
summaris
peak
concentr
denot
c
max
regimen
weight
categori
simul
pharmacokinet
profil
set
c
max
valu
input
pharmacodynam
model
propag
uncertainti
pharmacodynam
model
estim
desir
quantiti
use
draw
posterior
distribut
estim
per
thousand
mortal
differ
regimen
truncat
concentrationdepend
mortal
predict
vari
depend
draw
posterior
distribut
estim
mortal
ratio
given
sampl
size
hundr
highli
depend
prior
distribut
chosen
parametr
form
concentrationfat
curv
exampl
model
predict
mortal
order
per
figur
bottom
panel
approxim
background
rate
sudden
unexplain
death
young
adult
popul
therefor
render
predict
essenti
unverifi
pool
individu
patient
whole
blood
chloroquin
desethylchloroquin
concentr
outcom
largest
prospect
studi
hospit
selfpoison
cohort
figur
top
panel
patient
includ
analysi
treat
hospit
pari
whole
blood
concentr
measur
admiss
overal
mortal
patient
multipl
concentr
measur
n
reach
peak
concentr
admiss
presum
reach
peak
concentr
hospit
admiss
bayesian
logist
regress
use
estim
relationship
mortal
whole
blood
peak
chloroquin
concentr
figur
bottom
panel
specif
adjust
presenc
desethyl
metabolit
nonobserv
peak
concentr
patient
whole
blood
chloroquin
concentr
associ
mortal
ci
consid
lowest
mortal
reliabl
estim
deriv
data
follow
use
threshold
evalu
risk
fatal
toxic
chloroquin
regimen
evalu
use
two
differ
chloroquin
popul
pharmacokinet
model
simul
rang
expect
concentrationtim
curv
five
potenti
chloroquin
treatment
regimen
malaria
treatment
regimen
adult
weight
rang
whole
blood
concentrationtim
curv
summaris
peak
concentr
denot
c
max
pharmacokinet
model
estim
whole
blood
concentr
predict
wider
rang
valu
c
max
plasma
base
model
supplementari
figur
show
predict
distribut
kg
adult
assum
plasma
whole
blood
concentr
ratio
whole
blood
base
model
also
predict
higher
median
concentr
regimen
assum
plasma
whole
blood
ratio
gave
almost
ident
median
c
max
valu
pharmacokinet
model
fit
whole
blood
concentr
provid
higher
estim
fatal
toxic
predict
larger
varianc
c
max
distribut
henc
extrem
outlier
sensit
analysi
equival
output
plasma
base
model
shown
supplementari
materi
figur
adult
median
c
max
follow
base
equival
given
twice
daili
ten
day
figur
time
higher
median
c
max
malaria
treatment
regimen
bodi
weight
approxim
adult
receiv
twice
daili
dose
danger
zone
defin
concentr
comparison
patient
receiv
twice
daili
mainten
dose
ten
day
would
reach
concentr
take
account
uncertainti
around
threshold
valu
model
estim
fewer
per
thousand
receiv
twice
daili
dose
would
peak
concentr
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
figur
predict
risk
fatal
toxic
across
six
regimen
simul
whole
blood
pharmacokinet
model
panel
show
simul
distribut
c
max
valu
adult
five
treatment
regimen
malaria
treatment
regimen
vertic
red
shade
area
show
credibl
interv
mortal
threshold
concentr
panel
b
show
probabl
individu
cross
mortal
threshold
valu
function
bodi
weight
differ
regimen
log
scale
yaxi
panel
c
show
predict
mortal
per
thousand
six
regimen
function
bodi
weight
equival
output
use
plasma
pharmacokinet
model
given
supplementari
figur
mortal
threshold
figur
panel
b
thousand
adult
receiv
day
malaria
treatment
regimen
unusu
high
mgkg
dose
malaria
treatment
predict
reach
peak
concentr
coupl
pharmacokinet
model
pharmacodynam
model
estim
expect
weightdepend
fatal
ratio
five
chloroquin
treatment
regimen
truncat
concentrationfat
curv
mortal
threshold
take
account
concentr
go
threshold
figur
panel
administ
base
equival
chloroquin
phosphat
twice
daili
ten
day
trial
predict
result
absolut
mean
fatal
ratio
rang
credibl
interv
ci
ci
flat
dose
regimen
predict
result
fatal
rate
greater
per
thousand
weight
less
adult
day
regimen
could
result
per
thousand
mortal
ci
day
flat
regimen
without
load
dose
recommend
health
commiss
guangdong
provinc
adult
weigh
kg
model
predict
suggest
reduc
dose
given
lower
end
adult
weight
spectrum
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
chloroquin
hydroxychloroquin
alreadi
use
extens
often
high
dose
prevent
treat
despit
current
lack
convinc
evid
benefit
larg
randomis
trial
provid
definit
evid
treatment
efficaci
report
anoth
month
prevent
trial
take
longer
chloroquin
hydroxychloroquin
unusu
pharmacokinet
properti
enorm
total
appar
volum
distribut
v
chloroquin
hydroxychloroquin
slow
elimin
termin
halfliv
exceed
one
month
thu
distribut
process
rather
elimin
govern
blood
concentr
profil
first
day
follow
start
treatment
larg
singl
dose
danger
result
high
blood
concentr
drug
distribut
central
compart
hundr
time
smaller
total
v
convent
compartment
model
chloroquin
pharmacokinet
provid
approxim
distribut
process
high
concentr
caus
potenti
lethal
cardiovascular
nervou
system
toxic
concentr
depend
electrocardiograph
qr
widen
qt
prolong
death
usual
result
refractori
hypotens
ventricular
fibril
selfpoison
chloroquin
provid
unfortun
opportun
correl
drug
exposur
risk
iatrogen
death
toxicokineticpharmacodynam
model
develop
base
largest
prospect
seri
chloroquin
selfpoison
studi
singl
referr
centr
base
major
admiss
whole
blood
concentr
data
patient
whose
peak
concentr
occur
hospit
admiss
use
approxim
peak
concentr
remain
patient
overal
admiss
concentr
estim
approxim
lower
averag
peak
concentr
correspond
prior
expect
mean
interv
hospitalis
larg
selfpoison
cohort
hour
compar
averag
time
peak
concentr
oral
administr
hour
rang
hour
analysi
make
predict
hydroxychloroquin
toxic
pharmacolog
similar
chloroquin
clinic
featur
hydroxychloroquin
chloroquin
overdos
similar
although
hydroxychloroquin
consid
safer
wider
therapeut
margin
experiment
anim
unlik
chloroquin
larg
cohort
hydroxychloroquin
poison
base
pkpd
relationship
thu
given
avail
safeti
data
unlik
equival
hydroxychloroquin
concentr
chloroquin
danger
high
dose
chloroquin
regimen
use
borba
et
al
justifi
basi
recommend
health
commiss
guangdong
provinc
may
confus
salt
base
weight
chines
author
recommend
salt
twice
daili
two
tablet
compris
base
flat
dose
regimen
simul
addit
load
dose
day
accept
safeti
profil
wherea
regimen
triall
brazil
gave
dose
base
equival
almost
twice
recommend
chines
author
sever
limit
studi
retrospect
individu
patient
data
analysi
suicid
attempt
drug
alcohol
often
taken
well
although
none
acut
lethal
toxic
chloroquin
spectrophotometr
assay
method
separ
chloroquin
desethyl
metabolit
rel
insensit
desethychloroquin
gener
similar
biolog
properti
assay
perform
well
high
concentr
relev
studi
correct
presenc
metabolit
bayesian
model
correct
increas
uncertainti
around
threshold
concentr
associ
mortal
patient
manag
experienc
intensivist
intens
care
unit
close
clinic
laboratori
monitor
mortal
might
higher
less
well
support
set
overload
hospit
highincom
set
hypokalaemia
import
manifest
chloroquin
poison
contributor
tachyarrhythmia
high
dose
regimen
plasma
potassium
concentr
maintain
plasma
magnesium
concentr
predict
absolut
mortal
regimen
simul
work
sensit
parameter
pharmacokinet
model
c
max
usual
directli
observ
paramet
estim
data
larg
popul
pharmacokinet
studi
verifi
precis
c
max
predict
especi
tail
distribut
rang
mild
ill
sever
diseas
necessit
intens
care
case
fatal
ratio
highli
age
depend
potenti
toxic
treatment
regimen
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
balanc
sever
ill
chloroquin
benefit
patient
like
requir
high
exposur
howev
chloroquin
concentr
associ
mortal
understand
concentrationdepend
toxic
chloroquin
essenti
determin
riskbenefit
tradeoff
clinic
trial
treatment
regimen
hospitalis
patient
result
whole
blood
chloroquin
concentr
patient
accept
safeti
margin
author
declar
conflict
interest
mahidol
oxford
tropic
medicin
research
unit
fund
wellcom
trust
njw
senior
wellcom
trust
fellowship
jt
also
fund
bill
melinda
gate
foundat
specif
fund
receiv
work
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
figur
compar
concentr
fatalitycurv
obtain
use
retrospect
gather
data
blue
dash
line
n
prospect
gather
data
black
solid
line
n
paramet
logist
regress
correspond
maximum
likelihood
estim
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
figur
comparison
prior
distribut
thick
red
line
posterior
distribut
shown
histogram
four
paramet
model
intercept
term
logconcentr
coeffici
bia
term
patient
whose
peak
concentr
observ
fraction
concentr
due
chloroquin
metabolit
show
data
inform
respect
coeffici
log
concentr
desir
behaviour
given
know
chloroquin
low
dose
safe
see
metaanalysi
relat
bisquinolin
compound
piperaquin
show
normal
dose
mortal
unlik
greater
background
mortal
rate
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
figur
predict
c
max
distribut
kg
adult
plasma
pk
model
black
whole
blood
pk
model
red
differ
regimen
predict
plasma
concentr
scale
produc
approxim
whole
blood
concentr
area
curv
equal
yax
given
height
order
highlight
differ
width
predict
distribut
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
figur
pharmacokineticpharmacodynam
model
chloroquin
induc
mortal
top
pool
whole
blood
chloroquin
desethylchloroquin
concentr
admiss
sampl
prospect
studi
selfpoison
patient
data
shown
overlap
histogram
survivor
blue
n
nonsurvivor
red
n
overlap
area
shown
intermedi
burgundi
colour
bottom
bayesian
posterior
distribut
concentrationrespons
curv
mean
credibl
interv
admiss
whole
blood
chloroquin
concentr
death
shown
loglog
scale
horizont
dash
line
show
upper
percentil
plasma
pharmacokinet
model
six
regimen
consid
adult
vertic
red
shade
area
show
posterior
credibl
interv
concentr
associ
mortal
equival
output
whole
blood
pharmacokinet
model
shown
figur
main
text
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
figur
predict
risk
fatal
toxic
across
six
regimen
simul
plasma
pharmacokinet
model
panel
show
simul
distribut
c
max
valu
adult
four
regimen
consid
vertic
red
shade
area
show
credibl
interv
mortal
threshold
concentr
panel
b
show
probabl
individu
cross
mortal
threshold
valu
function
bodi
weight
differ
regimen
log
scale
yaxi
panel
c
show
predict
mortal
per
thousand
six
regimen
function
bodi
weight
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
